Monitoring of controlled drugs in England is still lacking in some aspects, commission findsBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a1125 (Published 04 August 2008) Cite this as: BMJ 2008;337:a1125
- Roger Dobson
Monitoring of controlled drugs in England has improved in the wake of the Shipman inquiry, but more work is still needed to minimise the risk of misuse by doctors, a new report concludes.
The report warns of a lack of confidence in sharing concerns about named professionals and of unclear lines of responsibility in some areas.
“Healthcare services have taken the first steps in minimising the risk of another Shipman,” said Anna Walker, chief executive of the Healthcare Commission, whose report details what has been done to improve monitoring since new regulations came into force in England last year. The regulations were a response to the conviction of the Manchester GP Harold Shipman …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial